Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Veridex, Mass Gen work on circulating tumor cell technology

Executive Summary

Johnson & Johnson’s Veridex LLC (cancer diagnostics) and Massachusetts General Hospital will together develop and market a next-generation circulating tumor cell (CTC) technology to capture, count, and characterize tumor cells located in a patient’s blood. The five-year deal is worth $30mm, consisting of a technology license fee and milestones, plus royalties.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies